Pyrimidine compound and medical use thereof
The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.
1. A compound represented by the following formula [I] or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
wherein
the
moiety is
R 1 and R 6 are the same or different and each is
a C 1-6 alkyl group,
a C 2-6 alkenyl group,
wherein the C 1-6 alkyl group and the C 2-6 alkenyl group are optionally substituted by 1 to 3 substituents selected from the following group A, or
wherein m is 0 or an integer of 1 to 4,
ring Cy is a C 3-12 carbon ring group or a heterocyclic group,
wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, the C 3-12 carbon ring group and the heterocyclic group are optionally substituted by 1 to 5 substituents selected from the following group B,
R 2 is
a C 2-6 alkenyl group,
wherein the C 2-6 alkenyl group is optionally substituted by 1 to 3 substituents selected from the following group A, or
wherein m is 0 or an integer of 1 to 4,
ring Cy is a C 3-12 carbon ring group or a heterocyclic group,
wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, the C 3-12 carbon ring group and the heterocyclic group are optionally substituted by 1 to 5 substituents selected from the following group B,
R 3 , R 4 , and R 5 are the same or different and each is
a hydrogen atom,
a hydroxyl group,
a C 1-6 alkyl group,
a C 2-6 alkenyl group,
wherein the C 1-6 alkyl group and the C 2-6 alkenyl group are optionally substituted by 1 to 3 substituents selected from the following group A,
a C 3-12 carbon ring group or
a heterocyclic group,
wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, and the C 3-12 carbon ring group and the heterocyclic group are optionally substituted by 1 to 5 substituents selected from the following group B, or
R 2 and R 3 are optionally linked to form a C 1-4 alkylene group, or R 4 and R 5 are optionally linked to form a C 1-4 alkylene group,
wherein group A is a group consisting of
1) a halogen atom,
2) a nitro group,
3) a cyano group,
4) a C 1-4 alkyl group,
5) —OR A1 wherein R A1 is a hydrogen atom or a C 1-4 alkyl group,
6) —SR A2 wherein R A2 is a hydrogen atom or a C 1-4 alkyl group,
7) —NR A3 R A4 wherein R A3 and R A4 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
8) —COOR A5 wherein R A5 is a hydrogen atom or a C 1-4 alkyl group,
9) —NR A6 COR A7 wherein R A6 is a hydrogen atom or a C 1-4 alkyl group, R A7 is a C 1-4 alkyl group, a C 3-12 carbon ring group or a heterocyclic group,
10) —NR A8 COOR A9 wherein R A8 and R A9 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
11) a C 3-12 carbon ring group and
12) a heterocyclic group,
wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom,
each of the C 1-4 alkyl groups of the above-mentioned 4), R A1 , R A2 , R A3 , R A4 , R A5 , R A6 R A7 , R A8 and R A9 is optionally substituted by the same or different 1 to 3 substituents selected from the following group C, and
each of the C 3-12 carbon ring groups of the above-mentioned 11) and R A7 , and the heterocyclic groups of 12) and R A7 is optionally substituted by the same or different 1 to 5 substituents selected from the following group C
group B is a group consisting of
1) a halogen atom,
2) a nitro group,
3) a cyano group,
4) a C 1-8 alkyl group,
5) a C 2-4 alkenyl group,
6) a C 2-4 alkynyl group,
7) —OR B1 wherein R B1 is a hydrogen atom or a C 1-4 alkyl group,
8) —SR B2 wherein R B2 is a hydrogen atom or a C 1-4 alkyl group,
9) —NR B3 R B4 wherein R B3 is a hydrogen atom, a C 1-4 alkyl group, a C 3-12 carbon ring group or a heterocyclic group, and R B4 is a hydrogen atom or a C 1-4 alkyl group,
10) —NR B5 COR B6 wherein R B5 is a hydrogen atom or a C 1-4 alkyl group, and R B6 is a hydrogen atom, a C 1-4 alkyl group, a C 3-12 carbon ring group or a heterocyclic group,
11) —NR B7 COOR B8 wherein R B7 and R B8 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
12) —NR B9 CONR B10 R B11 wherein R B9 , R B10 and R B11 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
13) —NR B12 CONR B13 OR B14 wherein R B12 , R B13 and R B14 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
14) —NR B15 SO 2 R B16 wherein R B15 is a hydrogen atom or a C 1-4 alkyl group, and R B16 is a C 1-4 alkyl group, a C 3-12 carbon ring group or a heterocyclic group,
15) —SO 2 —R B17 wherein R B17 is a C 1-4 alkyl group or a heterocyclic group,
16) —SO 2 NR B18 R B19 wherein RB 18 and R B19 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
17) —P(═O)(R B20 )(R B21 ) wherein R B20 and R B21 are the same or different and each is a C 1-4 alkyl group,
18) —COOR B22 wherein R B22 is a hydrogen atom or a C 1-4 alkyl group,
19) —CONR B23 R B24 wherein R B23 and R B24 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
20) —NR B25 SO 2 NR B26 R B27 wherein R B25 , R B26 and R B27 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
21) —NR B28 SO 2 NR B29 CONR B30 R B31 wherein R B28 , R B29 , R B30 and R B31 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
22) a C 3-12 carbon ring group and
23) a heterocyclic group
wherein each of the “C 1-8 alkyl group” of the above-mentioned 4), and the C 1-4 alkyl groups for R B1 to R B31 is optionally substituted by the same or different 1 to 3 substituents selected from the above-mentioned group A,
each of the C 2-4 alkenyl group of 5) and the C 2-4 alkynyl group of 6) is optionally substituted by the same or different 1 to 3 substituents selected from the above-mentioned group A,
the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, and
each of the C 3-12 carbon ring group of the above-mentioned 22), R B3 , R B6 and R B16 , and the heterocyclic group of the above-mentioned 23), R B3 , R B6 , R B16 and R B17 is optionally substituted by the same or different 1 to 5 substituents selected from the following group C, and
group C is a group consisting of
1) a halogen atom,
2) a cyano group,
3) a C 1-4 alkyl group,
4) —OR C1 wherein R C1 is a hydrogen atom or a C 1-4 alkyl group,
5) —NR C2 R C3 wherein R C2 and R C3 are the same or different and each is a hydrogen atom or a C 1-4 alkyl group,
6) —COOR C4 wherein R C4 is a hydrogen atom or a C 1-4 alkyl group and
7) an oxo group,
provided that when R 2 is a phenyl group, then R 1 is not a phenyl group.
2. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the compound is represented by the following formula: [I-1]
wherein each symbol in the formula is as defined in claim 1 .
3. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the compound is represented by the following formula: [I-3]
wherein each symbol in the formula is as defined in claim 1 .
4. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 1 is a C 1-6 alkyl group.
5. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 1 is
wherein m is 0, and ring Cy is a C 3-12 carbon ring group,
wherein the C 3-12 carbon ring group is optionally substituted by 1 to 5 substituents selected from group B of claim 1 .
6. The compound of claim 5 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 1 is a C 3-8 cycloalkyl group.
7. The compound of claim 6 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 1 is a cyclopropyl group.
8. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 2 is
wherein m is 0, and ring Cy is a C 3-12 carbon ring group or a heterocyclic group,
wherein the C 3-12 carbon ring group and the heterocyclic group are optionally substituted by 1 to 5 substituents selected from group B of claim 1 .
9. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 3 is a C 1-6 alkyl group.
10. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 4 is a hydrogen atom.
11. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 5 is a hydrogen atom.
12. The compound of any one of claims 1 , 2 and 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 6 is
wherein m is 0, and ring Cy is a C 3-12 carbon ring group or a heterocyclic group,
wherein the C 3-12 carbon ring group and the heterocyclic group are optionally substituted by 1 to 5 substituents selected from group B of claim 1 .
13. The compound of claim 1 , which is N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
14. The compound of claim 13 , wherein the compound is the sodium salt thereof.
15. The compound of claim 13 , wherein the compound is the hydrate thereof.
16. The compound of claim 13 , wherein the compound is the acetic acid solvate thereof.
17. The compound of claim 13 , wherein the compound is the dimethylsulfoxide solvate thereof.
18. The compound of claim 13 , wherein the compound is the ethanol solvate thereof.
19. The compound of claim 13 , wherein the compound is the nitromethane solvate thereof.
20. The compound of claim 13 , wherein the compound is the chlorobenzene solvate thereof.
21. The compound of claim 13 , wherein the compound is the 1-pentanol solvate thereof.
22. The compound of claim 13 , wherein the compound is the isopropyl alcohol solvate thereof.
23. The compound of claim 13 , wherein the compound is the ethylene glycol solvate thereof.
24. The compound of claim 13 , wherein the compound is the 3-methylbutanol solvate thereof.
25. A pharmaceutical composition comprising
(a) a compound of claim 1 or 13 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and
(b) a pharmaceutically acceptable carrier.
26. A pharmaceutical composition comprising
(a) a compound of claim 1 or 13 or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
(b) at least one antitumor compound that is not a compound of the formula [I]or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and
(c) a pharmaceutically acceptable carrier.